Edition:
United States

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

29.05SEK
15 Jun 2018
Change (% chg)

-0.15kr (-0.51%)
Prev Close
29.20kr
Open
29.15kr
Day's High
29.55kr
Day's Low
28.85kr
Volume
684,076
Avg. Vol
537,332
52-wk High
41.68kr
52-wk Low
25.25kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 0.77
Market Cap(Mil.): kr4,773.87
Shares Outstanding(Mil.): 164.33
Dividend: 0.28
Yield (%): 0.97

Financials

  KARO.ST Industry Sector
P/E (TTM): 198.51 240.92 34.18
EPS (TTM): 0.15 -- --
ROI: 0.65 -5.87 13.17
ROE: 1.26 -7.71 15.15

BRIEF-Karo Pharma Determines Terms For Rights Issue

* THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED

Apr 30 2018

BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln

* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

Apr 26 2018

BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue

* THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

Apr 04 2018

BRIEF-Karo Pharma Intends To Propose Dividend Of SEK 0.30 Per Share

* INTENDS TO PROPOSE DIVIDEND OF SEK 0.30 PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 03 2018

BRIEF-Karo Pharma Acquires Major Product Portfolio for EUR 260 Mln

* ‍ACQUIRES A PRODUCT PORTFOLIO FROM DANISH PHARMACEUTICAL COMPANY LEO PHARMA A/S FOR 260 MEURO​

Mar 01 2018

BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln

* Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO

Feb 22 2018

BRIEF-Karo Pharma Says RORgamma Project Is Not Shut Down

* SAYS RORGAMMA PROJECT IS NOT SHUT DOWN BUT CARRIES ON AS PLANNED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 11 2018

BRIEF-Karo Pharma Rights Issue Subscribed To 170 Percent

* RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 04 2018

Earnings vs. Estimates